Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moritz Bewarder

Showing results (31-40 of 64) with videos related to

Pageof 7
Sort By:
European Journal of Haematology|August 1, 2024
Comparison of R-CHOP-14 and R-mini-CHOP in older adults with diffuse large B-cell lymphoma-A retrospective multicenter cohort studyZelal Guel Dilbaz, Sophy Denker, Carla Ankermann, et al.
Scientific Reports|April 26, 2024
Hyper-N-glycosylated SEL1L3 as auto-antigenic B-cell receptor target of primary vitreoretinal lymphomasMichelle Elbert, Frank Neumann, Maximilian Kiefer, et al.
British Journal of Haematology|May 21, 2026
Plasmacytic markers as immunotherapeutic targets for primary CD20-negative aggressive B-cell lymphomasFrank Neumann, Claudia Schormann, Onur Cetin, et al.
Haematologica|February 23, 2023
Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R)-CHOPMoritz Bewarder, Dominic Kaddu-Mulindwa, Igor Age Kos, et al.
International Journal of Molecular Sciences|December 17, 2024
Cytomegalovirus-Specific T-Cell-Receptor-like Antibodies Target In Vivo-Infected Human Leukocytes Inducing Natural Killer Cell-Mediated Antibody-Dependent Cellular CytotoxicityMoritz Bewarder, Konstantinos Christofyllakis, Milena Petersen, et al.
Cancer Immunology, Immunotherapy : CII|April 18, 2020
Characterization of an HLA-restricted and human cytomegalovirus-specific antibody repertoire with therapeutic potentialMoritz Bewarder, Gerhard Held, Lorenz Thurner, et al.
Intensive Care Medicine Experimental|September 3, 2021
Killer immunoglobulin-like receptor 2DS5 is associated with recovery from coronavirus disease 2019Vadim Lesan, Moritz Bewarder, Carlos Metz, et al.
Frontiers in Immunology|May 28, 2026
Real-world comparison of anti-CD20 therapies: efficacy, infections, and immune profiles in a German cohortJakob Stögbauer, Moritz Bewarder, Linda Groß, et al.
Ejhaem|February 23, 2023
Ars2-containing bispecific, Fab- and IgG1-format BAR-bodies to target DLBCL cellsMaximilian Kiefer, Lorenz Thurner, Theresa Bock, et al.
Leukemia & Lymphoma|October 20, 2021
Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trialDominic Kaddu-Mulindwa, Vadim Lesan, Christian Berdel, et al.
Pageof 7

Showing results (31-40 of 64) with videos related to

Sort By:
Pageof 7
European Journal of Haematology|August 1, 2024
Comparison of R-CHOP-14 and R-mini-CHOP in older adults with diffuse large B-cell lymphoma-A retrospective multicenter cohort studyZelal Guel Dilbaz, Sophy Denker, Carla Ankermann, et al.
Scientific Reports|April 26, 2024
Hyper-N-glycosylated SEL1L3 as auto-antigenic B-cell receptor target of primary vitreoretinal lymphomasMichelle Elbert, Frank Neumann, Maximilian Kiefer, et al.
British Journal of Haematology|May 21, 2026
Plasmacytic markers as immunotherapeutic targets for primary CD20-negative aggressive B-cell lymphomasFrank Neumann, Claudia Schormann, Onur Cetin, et al.
Haematologica|February 23, 2023
Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R)-CHOPMoritz Bewarder, Dominic Kaddu-Mulindwa, Igor Age Kos, et al.
International Journal of Molecular Sciences|December 17, 2024
Cytomegalovirus-Specific T-Cell-Receptor-like Antibodies Target In Vivo-Infected Human Leukocytes Inducing Natural Killer Cell-Mediated Antibody-Dependent Cellular CytotoxicityMoritz Bewarder, Konstantinos Christofyllakis, Milena Petersen, et al.
Cancer Immunology, Immunotherapy : CII|April 18, 2020
Characterization of an HLA-restricted and human cytomegalovirus-specific antibody repertoire with therapeutic potentialMoritz Bewarder, Gerhard Held, Lorenz Thurner, et al.
Intensive Care Medicine Experimental|September 3, 2021
Killer immunoglobulin-like receptor 2DS5 is associated with recovery from coronavirus disease 2019Vadim Lesan, Moritz Bewarder, Carlos Metz, et al.
Frontiers in Immunology|May 28, 2026
Real-world comparison of anti-CD20 therapies: efficacy, infections, and immune profiles in a German cohortJakob Stögbauer, Moritz Bewarder, Linda Groß, et al.
Ejhaem|February 23, 2023
Ars2-containing bispecific, Fab- and IgG1-format BAR-bodies to target DLBCL cellsMaximilian Kiefer, Lorenz Thurner, Theresa Bock, et al.
Leukemia & Lymphoma|October 20, 2021
Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trialDominic Kaddu-Mulindwa, Vadim Lesan, Christian Berdel, et al.
Pageof 7